These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

799 related items for PubMed ID: 8895688

  • 1. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
    Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, Stamatoullas A, Monconduit M, Tilly H.
    Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
    [Abstract] [Full Text] [Related]

  • 2. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C, Waak M, Knopp A, Kleine HD, Kundt G, Leithäuser M, Hilgendorf I, Wolff D, Casper J, Freund M.
    Neoplasma; 2005 Nov; 52(5):402-10. PubMed ID: 16151585
    [Abstract] [Full Text] [Related]

  • 3. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S.
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [Abstract] [Full Text] [Related]

  • 4. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA, Le Beau MM.
    Chem Biol Interact; 2005 May 30; 153-154():187-95. PubMed ID: 15935816
    [Abstract] [Full Text] [Related]

  • 5. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M, Suchomel RW, Zöchbauer S, Brunner R, Lechner K, Pirker R.
    Clin Cancer Res; 1997 Aug 30; 3(8):1419-25. PubMed ID: 9815827
    [Abstract] [Full Text] [Related]

  • 6. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T.
    Haematologica; 2004 Sep 30; 89(9):1082-90. PubMed ID: 15377469
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C, Chelghoum Y, Plesa A, Elhamri M, Tigaud I, Michallet M, Dumontet C, Thomas X.
    Cancer; 2008 Feb 01; 112(3):572-80. PubMed ID: 18085638
    [Abstract] [Full Text] [Related]

  • 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L, Jarque I, Martín G, Sempere A, González-García Y, Gomis F, Pérez-Sirvent M, De La Rubia J, Sanz MA.
    Haematologica; 1998 Sep 01; 83(9):783-7. PubMed ID: 9825574
    [Abstract] [Full Text] [Related]

  • 9. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
    Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J.
    Cancer; 1997 Dec 01; 80(11 Suppl):2191-8. PubMed ID: 9395033
    [Abstract] [Full Text] [Related]

  • 10. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA.
    Best Pract Res Clin Haematol; 2007 Mar 01; 20(1):29-37. PubMed ID: 17336252
    [Abstract] [Full Text] [Related]

  • 11. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R.
    J Clin Oncol; 2010 Apr 20; 28(12):2101-7. PubMed ID: 20308656
    [Abstract] [Full Text] [Related]

  • 12. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.
    J Clin Oncol; 2010 Aug 20; 28(24):3890-8. PubMed ID: 20660833
    [Abstract] [Full Text] [Related]

  • 14. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M, Stipa E, Scimò MT, Masi M, Amadori S.
    Cancer; 1996 Jun 15; 77(12):2476-88. PubMed ID: 8640696
    [Abstract] [Full Text] [Related]

  • 15. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.
    Cascavilla N, Musto P, D'Arena G, Ladogana S, Matera R, Carotenuto M.
    Haematologica; 1997 Jun 15; 82(1):31-7. PubMed ID: 9107079
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
    van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ.
    Clin Cancer Res; 2005 Sep 15; 11(18):6520-7. PubMed ID: 16166428
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 15; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

  • 19. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C, Hassan HT.
    Leuk Res; 2006 Mar 15; 30(3):296-302. PubMed ID: 16112192
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology.
    Haematologica; 2002 Feb 15; 87(2):154-66. PubMed ID: 11836166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.